News
Finally, our analysis of a mixed lung neuroendocrine tumor identifies a population of putative progenitor cells that may give rise to both neuroendocrine and non-neuroendocrine (squamous) cells, ...
Ronald Acuna Jr. tied Bobby Bonds at the top of some elite baseball history on Monday night as the Atlanta Braves beat the New York Mets at Citi Field. Per @Sta ...
We would like to share ideas on the publication "Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung 1 ". The article explored the potential relationship ...
Karla Flores was diagnosed with a rare brain tumor. A misplaced MRI found a second, nearly inoperable, tumor on her spine.
Tarlatamab is a bispecific T-cell engager (BiTE) that binds to delta-like ligand-3 (DLL3) on small cell lung cancer (SCLC) cells and cluster of differentiation-3 on T cells, thereby delivering ...
Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American ...
A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients. The ...
The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, ...
For the organoid experiment, TRACERx patient–derived lung tumor organoid cells were cultured with human myeloid cells isolated from the lungs of immunodeficient mice engrafted with human TET2 ...
Olivia Williams opened up about her harrowing journey with pancreatic cancer, revealing she experienced years of misdiagnoses, dismissals by doctors.
A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results